Clinical Scorecard: FDA declines approval of ivonescimab for previously treated advanced NSCLC
At a Glance
Category
Detail
Condition
Clinical topic addressed by the source article: FDA rejects ivonescimab for lung cancer
Key Mechanisms
Mechanisms or clinical associations described in the source article.
Target Population
Patients or participants described in the source article.
Care Setting
Proposed treatment for locally advanced or metastatic NSCLC previously treated with EGFR TKIs; ivonescimab is not approved in the United States.
Key Highlights
Summit Therapeutics reported that the FDA issued a Complete Response Letter declining approval of ivonescimab plus platinum-containing chemotherapy for the proposed NSCLC indication.
According to Summit, the FDA determined that substantial evidence of effectiveness had not been established without a statistically significant overall survival improvement and that progression-free survival benefit alone did not support a favorable benefit-risk profile.
In the phase 3 HARMONi trial, the combination met dual primary progression-free survival endpoints.
Overall survival showed a favorable trend but did not reach statistical significance.
Summit reported that ivonescimab remains investigational in the United States and has marketing authorization in China.
Guideline-Based Recommendations
Diagnosis
Management
Monitoring & Follow-up
Risks
Patient & Prescribing Data
HARMONi enrolled patients with EGFR-mutated, locally advanced or metastatic nonsquamous NSCLC previously treated with a third-generation EGFR TKI.
The trial compared ivonescimab plus platinum-containing chemotherapy with placebo plus chemotherapy. The FDA declined approval for the proposed indication; ivonescimab is not approved in the United States.